ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… the Association for Research in Vision and Ophthalmology (ARVO) and the annual meeting of the American Society for … the Association for Research in Vision and Ophthalmology (ARVO) The conference is being held from April 28 – May 2, …
… Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting Corporate strategy to focus on … the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 1-4, 2022. Operational u pdates The …
… pipeline targeting LCA 10 and Usher syndrome at the ARVO annual meeting in May 2017 LEIDEN, the Netherlands, May … the Association for Research in Vision and Ophthalmology (ARVO) held on May 7 – 11, 2017 in Baltimore, MD, USA, the …
… and positive pre-clinical data were presented at the ARVO 2017 meeting. QR-110 has orphan drug designation (ODD) … positive pre-clinical proof of concept data at the ARVO 2017 meeting. In November, the first patient was dosed … positive pre-clinical data for QR-421a and QR-411 at the ARVO conference. QR-421a is being developed for the …
